Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

UPDATE ON THE CONNECTED TRANSACTION PROPOSED ACQUISITION OF 10% EQUITY INTEREST IN FINANCE COMPANY

We refer to the announcement (the "**Announcement**") of Shanghai Pharmaceuticals Holding Co., Ltd.* (the "**Company**") dated 26 July 2025, in relation to, the proposed Share Transfer Agreement, pursuant to which the Company proposed to acquire and SIIC Dongtan proposed to dispose 10% equity interest in Finance Company. Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Share Transfer Agreement has been executed by the Company and SIIC Dongtan on 8 September 2025 on the principal terms disclosed in the Announcement.

Save as disclosed above, all other information in the Announcement remains unchanged.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
YANG Qiuhua
Chairman

Shanghai, the PRC, 9 September 2025

As of the date of this announcement, the executive Directors of the Company are Mr. YANG Qiuhua, Mr. SHEN Bo, Mr. LI Yongzhong and Mr. DONG Ming; the non-executive Director is Mr. ZHANG Wenxue; and the independent non-executive Directors are Mr. GU Zhaoyang, Mr. Manson FOK, Mr. WANG Zhong and Ms. MAN Kwan.

* *For identification purpose only*